{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T09:16:01Z","timestamp":1767172561244,"version":"build-2238731810"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["R21DA056799"],"award-info":[{"award-number":["R21DA056799"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Individuals with opioid use disorder (OUD) are frequently hospitalized for injection-related medical complications, yet they often receive inadequate treatment for the OUD itself. We previously conducted a qualitative study to adapt an existing remotely delivered intensive outpatient program (IOP) specifically for hospitalized patients with OUD. We then conducted a pilot feasibility and acceptability study to assess the program.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The 4-week IOP consisted of asynchronous video content and in-person peer support. The primary outcomes were the feasibility of recruitment, acceptability of the treatment as assessed by the completion of videos, and engagement with the peer recovery coach. Secondary outcomes included OUD treatment retention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 12 participants, the mean age was 40.9 years, 58.3% were female, and 58.3% had an injection-related serious infection. Results demonstrated potentially acceptable recruitment feasibility (70.6%, 95% CI [48.9\u201392.3]), but the median percentage of video completion was only 2% (range: 0\u201316%) and the median percentage of engagement with recovery coach was 31.8% (range: 16.7\u201366.7%). All participants received medications for OUD (MOUD) during the hospital stay (methadone 83%, buprenorphine 17%), and 33.3% remained retained in MOUD treatment at 28 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Hospitalized patients with OUD desired additional support through an IOP along with MOUD. While recruitment feasibility was acceptable, the overall program was not. Future research should explore IOP content that is more personalized and engaging while also including peer support.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13722-025-00589-4","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T12:21:45Z","timestamp":1754050905000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pilot testing a novel remotely delivered intensive outpatient program for hospitalized patients with opioid use disorder"],"prefix":"10.1186","volume":"20","author":[{"given":"Veronica","family":"Szpak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Velez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Prostko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Rosenblum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyndon J.","family":"Aguiar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger D.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joji","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"issue":"3","key":"589_CR1","doi-asserted-by":"publisher","first-page":"ofw157","DOI":"10.1093\/ofid\/ofw157","volume":"3","author":"AG Wurcel","year":"2016","unstructured":"Wurcel AG, Anderson JE, Chui KKH, et al. Increasing infectious endocarditis admissions among young people who inject drugs. Open Forum Infect Dis. 2016;3(3):ofw157. https:\/\/doi.org\/10.1093\/ofid\/ofw157.","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"589_CR2","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1377\/hlthaff.2015.1424","volume":"35","author":"MV Ronan","year":"2016","unstructured":"Ronan MV, Herzig SJ. Hospitalizations related to opioid abuse\/dependence and associated serious infections increased sharply, 2002-12. Health Aff (Millwood). 2016;35(5):832\u20137. https:\/\/doi.org\/10.1377\/hlthaff.2015.1424.","journal-title":"Health Aff (Millwood)"},{"key":"589_CR3","unstructured":"Weiss A, Elixhauser A, Barrett M, Steiner C, Bailey M, O\u2019Malley L. Opioid-Related Inpatient Stays and Emergency Department Visits by State, 2009\u20132014. Published online January 2017. https:\/\/www.hcup-us.ahrq.gov\/reports\/statbriefs\/sb219-Opioid-Hospital-Stays-ED-Visits-by-State.jsp"},{"issue":"11","key":"589_CR4","doi-asserted-by":"publisher","first-page":"e0242165","DOI":"10.1371\/journal.pone.0242165","volume":"15","author":"J Capizzi","year":"2020","unstructured":"Capizzi J, Leahy J, Wheelock H, et al. Population-based trends in hospitalizations due to injection drug use-related serious bacterial infections, oregon, 2008 to 2018. PLoS ONE. 2020;15(11):e0242165. https:\/\/doi.org\/10.1371\/journal.pone.0242165.","journal-title":"PLoS ONE"},{"issue":"7","key":"589_CR5","doi-asserted-by":"publisher","first-page":"e2421740","DOI":"10.1001\/jamanetworkopen.2024.21740","volume":"7","author":"SD Kimmel","year":"2024","unstructured":"Kimmel SD, Walley AY, White LF, et al. Medication for opioid use disorder after serious Injection-Related infections in Massachusetts. JAMA Netw Open. 2024;7(7):e2421740. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.21740.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"589_CR6","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/cid\/ciz869","volume":"71","author":"S Straw","year":"2020","unstructured":"Straw S, Baig MW, Gillott R, et al. Long-term outcomes are poor in intravenous drug users following infective endocarditis, even after surgery. Clin Infect Dis. 2020;71(3):564\u201371. https:\/\/doi.org\/10.1093\/cid\/ciz869.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"589_CR7","doi-asserted-by":"publisher","first-page":"e1003247","DOI":"10.1371\/journal.pmed.1003247","volume":"17","author":"JH Kim","year":"2020","unstructured":"Kim JH, Fine DR, Li L, et al. Disparities in united States hospitalizations for serious infections in patients with and without opioid use disorder: A nationwide observational study. PLoS Med. 2020;17(8):e1003247. https:\/\/doi.org\/10.1371\/journal.pmed.1003247.","journal-title":"PLoS Med"},{"key":"589_CR8","doi-asserted-by":"publisher","unstructured":"Suzuki J, Johnson JA, Montgomery MW, et al. Long-term outcomes of injection Drug-related infective endocarditis among people who inject drugs. J Addict Med Published Online Oct. 2019;18. https:\/\/doi.org\/10.1097\/ADM.0000000000000572.","DOI":"10.1097\/ADM.0000000000000572"},{"issue":"10","key":"589_CR9","doi-asserted-by":"publisher","first-page":"e2016228","DOI":"10.1001\/jamanetworkopen.2020.16228","volume":"3","author":"SD Kimmel","year":"2020","unstructured":"Kimmel SD, Walley AY, Li Y, et al. Association of treatment with medications for opioid use disorder with mortality after hospitalization for injection drug use-Associated infective endocarditis. JAMA Netw Open. 2020;3(10):e2016228. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.16228.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"589_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/ADM.0000000000000501","volume":"13","author":"R Saitz","year":"2019","unstructured":"Saitz R. Treatment for opioid addiction must be offered in general hospitals: but how?? J Addict Med. 2019;13(2):83\u20134. https:\/\/doi.org\/10.1097\/ADM.0000000000000501.","journal-title":"J Addict Med"},{"key":"589_CR11","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.12788\/jhm.3311","volume":"14","author":"H Englander","year":"2019","unstructured":"Englander H, Priest KC, Snyder H, Martin M, Calcaterra S, Gregg J. A call to action: hospitalists\u2019 role in addressing substance use disorder. J Hosp Med. 2019;14:E1\u20134. https:\/\/doi.org\/10.12788\/jhm.3311.","journal-title":"J Hosp Med"},{"key":"589_CR12","doi-asserted-by":"publisher","unstructured":"Wakeman SE, Metlay JP, Chang Y, Herman GE, Rigotti NA. Inpatient Addiction Consultation for Hospitalized Patients Increases Post-Discharge Abstinence and Reduces Addiction Severity. J Gen Intern Med. Published online May 19, 2017. https:\/\/doi.org\/10.1007\/s11606-017-4077-z","DOI":"10.1007\/s11606-017-4077-z"},{"key":"589_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsat.2017.05.007","volume":"79","author":"P Trowbridge","year":"2017","unstructured":"Trowbridge P, Weinstein ZM, Kerensky T, et al. Addiction consultation services - Linking hospitalized patients to outpatient addiction treatment. J Subst Abuse Treat. 2017;79:1\u20135. https:\/\/doi.org\/10.1016\/j.jsat.2017.05.007.","journal-title":"J Subst Abuse Treat"},{"key":"589_CR14","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.","journal-title":"BMJ"},{"key":"589_CR15","doi-asserted-by":"publisher","unstructured":"Larochelle MR, Bernson D, Land T et al. Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study. Ann Intern Med. Published online June 19, 2018. https:\/\/doi.org\/10.7326\/M17-3107","DOI":"10.7326\/M17-3107"},{"issue":"2","key":"589_CR16","doi-asserted-by":"publisher","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"3","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE, Larochelle MR, Ameli O, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.20622.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"589_CR17","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1176\/appi.ps.201300249","volume":"65","author":"D McCarty","year":"2014","unstructured":"McCarty D, Braude L, Lyman DR, et al. Substance abuse intensive outpatient programs: assessing the evidence. Psychiatr Serv. 2014;65(6):718\u201326. https:\/\/doi.org\/10.1176\/appi.ps.201300249.","journal-title":"Psychiatr Serv"},{"key":"589_CR18","unstructured":"Substance Abuse and Mental Health Services Administration. Substance abuse: clinical issues in intensive outpatient treatment. treatment.Improvement protocol (TIP) series, 47. Published online 2006."},{"key":"589_CR19","doi-asserted-by":"publisher","first-page":"100546","DOI":"10.1016\/j.abrep.2024.100546","volume":"19","author":"V Szpak","year":"2024","unstructured":"Szpak V, Prostko S, Weiss RD, Suzuki J. Developing a remotely delivered intensive outpatient program adapted for hospitalized patients with opioid use disorder: A qualitative study. Addict Behav Rep. 2024;19:100546. https:\/\/doi.org\/10.1016\/j.abrep.2024.100546.","journal-title":"Addict Behav Rep"},{"key":"589_CR20","doi-asserted-by":"publisher","unstructured":"Sobell L, Sobell M. Timeline Follow-Back for alcohol consumption. Published Online May. 2012;7. https:\/\/doi.org\/10.1037\/t06202-000.","DOI":"10.1037\/t06202-000"},{"issue":"3","key":"589_CR21","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jsat.2012.07.013","volume":"44","author":"JS Cacciola","year":"2013","unstructured":"Cacciola JS, Alterman AI, DePhilippis D, et al. Development and initial evaluation of the brief addiction monitor (BAM). J Subst Abuse Treat. 2013;44(3):256\u201363. https:\/\/doi.org\/10.1016\/j.jsat.2012.07.013.","journal-title":"J Subst Abuse Treat"},{"key":"589_CR22","doi-asserted-by":"publisher","first-page":"109057","DOI":"10.1016\/j.drugalcdep.2021.109057","volume":"229","author":"B Boyett","year":"2021","unstructured":"Boyett B, Wiest K, McLeod LD, et al. Assessment of craving in opioid use disorder: psychometric evaluation and predictive validity of the opioid craving VAS. Drug Alcohol Depend. 2021;229:109057. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.109057.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"589_CR23","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.amepre.2009.02.002","volume":"36","author":"DJ Bowen","year":"2009","unstructured":"Bowen DJ, Kreuter M, Spring B, et al. How we design feasibility studies. Am J Prev Med. 2009;36(5):452\u20137. https:\/\/doi.org\/10.1016\/j.amepre.2009.02.002.","journal-title":"Am J Prev Med"},{"issue":"1","key":"589_CR24","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1080\/07853890.2022.2068805","volume":"54","author":"SL Proctor","year":"2022","unstructured":"Proctor SL. Rewarding recovery: the time is now for contingency management for opioid use disorder. Ann Med. 2022;54(1):1178\u201387. https:\/\/doi.org\/10.1080\/07853890.2022.2068805.","journal-title":"Ann Med"},{"key":"589_CR25","doi-asserted-by":"publisher","first-page":"e43304","DOI":"10.2196\/43304","volume":"7","author":"J Suzuki","year":"2023","unstructured":"Suzuki J, Loguidice F, Prostko S, et al. Digitally assisted peer recovery coach to facilitate linkage to outpatient treatment following inpatient alcohol withdrawal treatment: Proof-of-Concept pilot study. JMIR Form Res. 2023;7:e43304. https:\/\/doi.org\/10.2196\/43304.","journal-title":"JMIR Form Res"},{"key":"589_CR26","doi-asserted-by":"publisher","first-page":"108248","DOI":"10.1016\/j.jsat.2020.108248","volume":"122","author":"JF Magidson","year":"2021","unstructured":"Magidson JF, Regan S, Powell E, et al. Peer recovery coaches in general medical settings: changes in utilization, treatment engagement, and opioid use. J Subst Abuse Treat. 2021;122:108248. https:\/\/doi.org\/10.1016\/j.jsat.2020.108248.","journal-title":"J Subst Abuse Treat"}],"updated-by":[{"DOI":"10.1186\/s13722-025-00601-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000}}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00589-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-025-00589-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00589-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T06:53:27Z","timestamp":1757487207000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-025-00589-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["589"],"URL":"https:\/\/doi.org\/10.1186\/s13722-025-00589-4","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"18 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The country name in the third affiliation has been corrected.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Mass General Brigham (MGB) IRB. Participants signed an informed consent form and were provided with a copy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Weiss reports consultation with Alkermes and Eli Lilly and Company. All other authors report no conflicts of interest. The authors alone are responsible for the content and writing of this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"NCT05817825.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trials registration"}}],"article-number":"61"}}